Clinical Trial Update: Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D [Phase 2]

View source ↗

Summary

Phase 2 randomized open-label crossover study of a novel pram-insulin co-formulation in adults with type 1 diabetes completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• pram-insulin co-formulation (pram-insulin co-formulation)

Snippet

Sponsor: Xeris Pharmaceuticals | Conditions: Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus | Phase 2 | Status: COMPLETED | Results posted: 2024-03-27